Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Phase 1

mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults

NCT07557602 · tracked via the Priya Life Science Australia tracker
Sponsor
Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company
Phase
Phase 1
Started
2026-05-04
Last updated
2026-04-29

Condition(s) studied

EBV

Investigational drug(s) / intervention(s)

VXCO-102Placebo

VXCO-102: Sterile liquid for injection

Placebo: 0.9% sodium chloride (BP grade)

Study summary

This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
25 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Aged 18 to 25 years, inclusive * Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment Exclusion Criteria: * Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation * Likely or confirmed myocarditis or pericarditis * Prior receipt of an investigational EBV vaccine * Prior receipt of a licensed vaccine within 56 days prior to Day 1 * Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study. * For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study Note: Other inclusion and exclusion criteria apply.

Primary outcome measure(s)

  • Number of Participants with Solicited Local and Systemic Reactions — 7 days after each product administration
  • Number of Participants with Unsolicited Adverse Events — Up to 28 days after each product administration
  • Number of Participants with Serious Adverse Events (SAEs) including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events of Special Interest (AESIs) — Day 1 to end of study (Day 357)

Trial sites (2)

FacilityCityRegionStatus
Q-Pharm Pty Ltd/Nucleus Network Pty Ltd Herston Queensland
Nucleus Network Pty Ltd Melbourne Victoria
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07557602 on ClinicalTrials.gov ↗ ← All trials in Australia